Agreement - June 2, 2021
Novo Nordisk enters agreement with Heartseed
Heartseed Inc. and Novo Nordisk A/S have entered into an exclusive worldwide collaboration and license agreement for development, manufacturing and commercialization of Heartseed’s HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure. “Through this […]